All In MedTech

Company

Elucid Bioimaging

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.

Financing

Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.

Private

Latest round: equity, $36.5M raised of $80.0M sought, first sale Oct 10, 2025, 9 investors.

Funding rounds (Form D)

One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.

First saleTypeRaisedRound sizeInvestorsExemption and agentFiling
Oct 10, 2025Equity$36.5M$80.0M9Rule 506(b)Form D ↗Oct 22, 2025

2 more funding rounds with a free account

Company details

From the company's latest Form D.

Legal name
Elucid Bioimaging Inc.
Headquarters
Boston, Massachusetts
Incorporated
Delaware over five years before filing
Entity type
Corporation
Revenue range
Decline to Disclose
Industry filed under
Biotechnology

Executives, directors and promoters

As listed on the latest Form D.

    8 more people on the filing with a free account

    Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.

    Investors

    5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors from funding announcements and the firms' own portfolio pages.

    The investor database is free with an account

    For Elucid Bioimaging we have 2 government grants totalling $4.6M.

    Sign up free with your name, company and ZIP code to see the 5%+ shareholders and government grant funders behind device companies.

    Latest FDA decisions

    Search the Clearance Tracker

    5 more FDA decisions with a free account

    Device trials

    Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

    Open in the Trial Radar
    • NCT06018194 · 439 participants · Start Sep 1, 2023 · Primary completion Jul 28, 2025

      Device: ElucidVivo · For: Coronary Artery Disease

      Sites: Beverly Hills, California; Atlanta, Georgia; Fort Wayne, Indiana · 8 sites in all

    2 more trials with a free account

    Adverse event reports received per month

    Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

    Search the MAUDE Monitor

    No reports to chart for this view.

    Device types named most often

    Last 12 months, by FDA product code. A company that sells more gets more reports.

    No device types to rank.

    Brand names named most often

    Last 12 months, as written on the reports. One product can appear under several spellings.

    No brand names to rank.

    Recent recalls

    From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

    No recalls under this name in FDA's data.

    Back to all tools

    For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.